What does thrombophilia testing mean for patients or their families? Do you know when and who to test for thrombophilia? In this podcast, experts Prof. Saskia Middeldorp and Prof. Jean Connors explore the diagnostic challenges for thrombophilia and which patients can benefit most from screening. In specific situations, testing can be crucial, but not always. Before testing, it is important to understand whether testing is needed and consider how it will provide support for decision making. ASH guidelines may be helpful. The experts discuss how these recommendations should be applied in general practice, as some caution is recommended.

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/hemostasis-connect/programmes/thrombophilia-testing-part2/

Or go to the video on YouTube: https://youtu.be/uvXTtZHdT1k

Want to find out more? Listen to the other episode in the series:

Episode 1- Thrombophilia: Clinical overview and impact on patients

https://youtu.be/vy6r3JJLkG8?si=wXro9w7XYV6XS66U

https://cor2ed.com/hemostasis-connect/programmes/thrombophilia-part1/

The medical experts in this podcast express their own views, not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Pentapharm

This educational podcast is developed by cor2ed.com

Innovation is the key to achieving success in the future, including recent scientific research to explore novel therapeutic options to improve the treatment of severe postpartum hemorrhage (PPH). If you're curious about the latest advancements in this field and how they can impact future treatment strategies for women who suffer from severe PPH, then listen to the fourth and final part of a podcast series on severe PPH.

Experts will discuss the latest treatment advances and their perception of how the management of PPH will evolve in the future.

Don't miss out on this opportunity to learn more about the latest scientific breakthroughs that can transform the lives of women suffering from PPH.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/severe-pph-treatment-developments/

Or go to the video on YouTube: https://www.youtube.com/watch?v=6HXtMNxgr1c

The medical experts in this podcast express their own views, not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Novo Nordisk.

This educational podcast is developed by cor2ed.com.

Thrombophilia: Clinical overview and impact on patients

What do you know about thrombophilia? Is it acquired or inherited, and what is the impact on patients? This is the first in a 2-part podcast series focusing on Thrombophilia.

In this episode, you will hear from Prof. Cedric Hermans, who is the Head of the division of Hematology, the Hemostasis and Thrombosis Unit and Hemophilia center of the Saint-Luc University hospital in Brussels, Belgium, and Prof. Sabine Eichinger, who is the Head of the Coagulation Clinic at the Medical University of Vienna, Austria. The experts discuss the main causes and symptoms of thrombophilia and the potential implications for the patient. They share their knowledge on the differences between acquired or inherited thrombophilia and discuss which specific patients can benefit from screening to prevent overtreatment or undertreatment. 

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/hemostasis-connect/programmes/thrombophilia-podcast-series-part-1/

Or go to the video on YouTube: https://youtu.be/vy6r3JJLkG8

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Pentapharm.

This educational podcast is developed by cor2ed.com.

Gene therapy and gene-modified cell therapies have a great potential for rare diseases to either help patients to cure their disease or improve their lives. Did you know that gene therapy will probably become a major treatment option for many rare diseases in the near future? Listen as expert hematologists delve into this topic and take hemophilia as a practical example.

Join Prof. Cédric Hermans (Head of the Division of Haematology, the Hemostasis and Thrombosis Unit and the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium) and Prof. Miguel Escobar (Professor of Medicine and Pediatrics, University of Texas Health Science Center at Houston-McGovern Medical School and University of Texas M.D. Anderson Cancer Center Medical Director, Gulf States Hemophilia & Thrombophilia Center Houston, USA) as they engage in a conversation about the potential of gene and gene-modified cell therapies in rare diseases, and how early gene therapies have been implemented as a treatment approach for rare diseases, such as leber congenital amaurosis, spinal muscular atrophy, beta-thalassemia, adrenoleukodystrophy, and hemophilia.

The experts explore hemophilia as an example of how gene therapy has become a reality within rare diseases. They discuss why we need gene therapy for rare disease, what gene therapy and gene modified cell therapy is, and how this has become a reality in hemophilia, and look to the future of gene therapy for rare diseases. Finally they reflect on the importance of a multidisciplinary approach.

- Access information on the programme, the clinical takeaways, the flashcard and the transcript here https://cor2ed.com/hemostasis-connect/programmes/gene-therapy-rare-diseases/

Find out about the experts Prof Cedric Hermans and Prof. Miguel Escobar. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from The American Society of Gene + Cell Therapy and Pfizer.

Thrombotic risk is a constant threat in perioperative patients, but it has decreased with the evolution of surgical technology.  Do you know how to minimise the risk of thrombosis in your surgical patients?  Learn from expert colleagues from the University of Basel, Switzerland: Prof. Dimitrios Tsakiris (hematologist) and Prof. Daniel Bolliger (anesthesiologist).

 In this podcast episode the two experts discuss the pathophysiology of perioperative thrombosis, how to apply perioperative thromboprophylaxis and consider special considerations such as the use of aspirin following orthopedic surgery, when to monitor anticoagulants and the use of inferior vena cava (IVC) filters as thromboprophylaxis.

 This is the final episode podcast in a four-part series on thrombosis in various clinical conditions.

Extended anticoagulation beyond the initial 3 months is indicated for all types of VTE, except in surgery-or trauma-VTE or in patients at high risk of bleeding. Are you up to date on the latest treatment options for VTE and their duration?  Expert haematologists Prof. Dimitrios Tsakiris (University of Basel, Switzerland) and Prof. Jerzy Windyga (Institute of Haematology and Transfusion Medicine, Warsaw, Poland) engage in a discussion on this important topic.

This is the third podcast in a four-part series on thrombosis in various clinical conditions. In this podcast we focus on anti-thrombotic treatment for VTE and how long optimal treatment should be.

In this podcast, Prof. Andra H. James (Professor Emeritus of Obstetrics and Gynecology, Division Maternal Fetal Medicine, Duke University Hospital, Durham, North Carolina, US) and Dr Maria Elisa Mancuso (Senior Haematology Consultant at the Center for Thrombosis and Hemorrhagic Diseases of IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy) discuss various treatment options for severe postpartum haemorrhage (also called PPH).

Experts discuss what causes PPH and how to determine the risk before and during labour with algorithms and other helpful tools. The discussion moves to when haematologic expertise is required and how collaboration can be optimized to provide the best care for patients. Furthermore, the experts share their learnings from clinical practice through discussion of specific patient cases, including patients with and without underlying bleeding disorders, as well as where haemostatic agents fit in the protocol.

In this podcast episode, Prof Dimitrios Tsakiris (Haematologist, Basel University, Switzerland) and Dr Lars Asmis (Haematologist, University of Zurich, Switzerland) discuss the association between thrombosis and cancer. 

Experts discuss how different tumours affect the risk for thrombosis in patients and genetic disorders such as thrombophilia. They cover multiple scores (Khorana, Vienna, PROTECHT and Pabinger) that might help to categorise thrombosis risk in oncology patients.

The discussion moves to how cancer patients with thrombosis should be treated and the duration of treatment of low molecular weight heparins and direct oral anticoagulants (DOACs), with reference to the CLOT study and recent guidelines. In addition, they discuss whether there should be a different approach with hospital in- and out-patients

 Finally, both experts discuss anticoagulation and oncocardiology and the higher incidences of atrial fibrillation reported in cancer patients.